Active substances
Budesonide + Formterol
- SFDA 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| BUFOMIX 160/4.5MCG EASYHALER | 160,4.5 µg,µg | Inhalation powder · Inhalation use | 1 Inhaler | SAR 158.00 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| SYMBICORT 80 MCG/4.5 MCG TURBOHALER | 80,4.5 µg,µg | Inhalation powder · Inhalation use | 1 Inhaler | SAR 116.70 | NCE · Prescription | AstraZeneca | Valid |
| SYMBICORT TURBUHALER | 160,4.5 µg,µg | Inhalation powder · Inhalation use | 1 Inhaler | SAR 169.80 | NCE · Prescription | AstraZeneca | Valid |
Indications — CHI Daman Drug Formulary
ASTHMA; CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD); GRAFT VERSUS HOST DISEASE
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.